The drugmaker expects to apply for full US approval in May.See more stories on Insider's business pagePfizer outlined a busy 2021 for its coronavirus vaccine on Tuesday, as executives for the drugmaker projected the shot will bring in $26 billion in revenues on the year.
Even though the shot is already authorized in the US and elsewhere, there's tons of research going on to expand the vaccine's impact. In particular, Pfizer is studying the vaccine in children of all ages, going all the way down to babies. The company also expects to have data this year for a new version of its shot that doesn't need to kept at any unusually low temperatures.
Pfizer's shot, co-developed with the German biotech BioNTech, was the first COVID-19 vaccine authorized in the US. More than 130 million doses have been administered in the US so far,One slide in Pfizer's earnings presentation on Tuesday summarizes the cascade of news the New York pharmaceutical giant expects over the next few months:Gearing up for more authorizations through the end of 2021Currently, regulators issued an emergency use authorization for the shot.
Finally, Pfizer is hoping it will be able to roll out its vaccine into the pediatric population throughout 2021. The company is currently waiting on an FDA decision to OK the shot for ages 12-15. The vaccine is currently authorized for use in anyone 16 years old and up. In September, Pfizer anticipates clinical trial results showing whether or not the shot works in children aged 2-11. The final step down for kids — from 6-month-old babies to 2-year-olds — should produce data in November, according to Pfizer's projections.Sign up for notifications from Insider! Stay up to date with what you want to know.